San Diego-based MabVax Therapeutics, a biotechnology firm focused on vaccine and antibody therapies for treating cancer, said today that it has received a $1.1M, Phase 2 Small Business Technology Transfer Program Award (STTR) from the National Cancer Institute. The firm said the grant is for two years, and will go towards development of the company's projects focused on characterization of human antibodies to sialyl-Lewis A (sLeA). Mabvax said it believes sLeA could have an important role in the treatment and prevention of recurrent cancer.
Top NewsTuesday, August 10, 2010
MabVax Gets $1.1M In STTR Grant